Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.48 |
| ▸ | F10 | P00742 | 12/20 | 0.48 |
| ▸ | PLG | P00747 | 6/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.47 |
| ▸ | PROC | P04070 | 1/20 | 0.47 |
| ▸ | MASP2 | O00187 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | TMPRSS11D | O60235 | 6/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562905 | 1.00 | F2 (0.48) | F2F10PLGKLKB1PROC | |
| SCHEMBL12127052 | 0.92 | F2 (0.44) | F2F10PLGKLKB1PROC | |
| SCHEMBL17381507 | 0.89 | F2 (0.48) | F2F10PLGKLKB1PROC | |
| SCHEMBL17381407 | 0.88 | F2 (0.44) | F2F10PLGKLKB1PROC | |
| SCHEMBL20560497 | 0.86 | F2 (0.58) | F2F10PLGKLKB1PROC | |
| SCHEMBL1328107 | 0.86 | F2 (0.58) | F2F10PLGKLKB1PROC | |
| SCHEMBL8289994 | 0.83 | F2 (0.55) | F2F10PLGKLKB1PROC | |
| SCHEMBL20012115 | 0.83 | F2 (0.57) | F2F10PLGKLKB1PROC | |
| SCHEMBL2562899 | 0.82 | MASP2 (0.42) | F2MASP2NFKB1PSMB5NFKB2 | |
| SCHEMBL8289977 | 0.82 | F2 (0.61) | F2F10PLGKLKB1PROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238020-B2 | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130089504-A1 | Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011133178-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133179-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089504-A1 | Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug | TMPRSS15, DNPEP, PGA5 | F2 843/4885F10 1427/4885PLG 90/4885 |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | CYP2C9, ACHE, COMT | F2 1981/4885F10 2644/4885PLG 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.